Skip to content

Categories:
  • No categories

Enters Into Exclusive Distribution Agreement

“We are pleased to conclude this agreement with United Safety as we focus on the important ground transportation sector with a well-established and successful global partner,” said Paul Ghezzi, CEO of Kontrol. “The United Safety team shares our passion and commitment to creating safe spaces for all.” Based in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) has developed life-saving diagnostic solutions for detecting a large number of cancers. Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer screening technology that uses peripheral blood tests, which thoroughly study the impact of cancer on the immune system and seek biochemical changes in blood cells and mononuclear plasma. Todos` two internal TMB-1 and TMB-2 cancer screening tests have received CE markings in Europe and are currently being studied prior to commercialization with their distributor Orot (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S. medical diagnostics company Provista Diagnostics, Inc. to acquire the rights to its CLIA/CAP certified laboratory, based in Alpharetta, Georgia and ® breast cancer patent. The transaction is expected to close in the second quarter of 2020. Syngenta ANZ has entered into an exclusive distribution agreement with Sinochem International Australia. From 1 July 2020, Sinochem International`s full range of products in Australia and New Zealand will be marketed by Syngenta ANZ. “Given that todos is a niche provider of COVID 19 test solutions for laboratories, health care providers and policy makers around the world, we have identified areas in the field of diagnostic testing that require significant innovation, including the development of an easy-to-use “Active Infection” test that can be used on the screening site before accessing high-risk environments,” said Gerald E.

Commission, President and CEO of Todos. We believe that this technology gives us proprietary support in a space that calls for new solutions to overcome the biological limitations of current approaches. When we start marketing our COVID-19 portfolios of molecules and antibodies, this proprietary technology will give us a marketing advantage because customers want to partner with long-term partners. Integrated mobile phone analytics technology enables data protection-compliant integration with a variety of employer-based contact, telehealth and health monitoring solutions that enter the market. Rehovot, Israel, and NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Todos Medical Ltd.

Posted in Uncategorized.

0 Responses

Stay in touch with the conversation, subscribe to the RSS feed for comments on this post.